Related papers: Quantifying Hippocampal Shape Asymmetry in Alzheim…
The hippocampus is one of the most studied neuroanatomical structures due to its involvement in attention, learning, and memory as well as its atrophy in ageing, neurological, and psychiatric diseases. Hippocampal shape changes, however,…
Alzheimer's disease (AD) and mild cognitive impairment (MCI) are associated with progressive gray matter loss, particularly in medial temporal structures. In this study, CAT12/SPM12 voxel-based morphometry was applied to baseline…
We describe a new method to automatically discriminate between patients with Alzheimer's disease (AD) or mild cognitive impairment (MCI) and elderly controls, based on multidimensional classification of hippocampal shape features. This…
Alzheimer's disease is a progressive form of dementia that results in problems with memory, thinking, and behavior. It often starts with abnormal aggregation and deposition of beta amyloid and tau, followed by neuronal damage such as…
In this article, we analyze the morphometry of hippocampus in subjects with very mild dementia of Alzheimer's type (DAT) and nondemented controls and how it changes over a two-year period. Morphometric differences with respect to a template…
Alzheimer's disease (AD) is the most common type of dementia accompanied with brain atrophy. Structural measurements of brain atrophy in specific brain structures such as hippocampus using magnetic resonance imaging (MRI) have been reported…
Volume change measures derived from longitudinal MRI (e.g. hippocampal atrophy) are a well-studied biomarker of disease progression in Alzheimer's Disease (AD) and are used in clinical trials to track the therapeutic efficacy of…
Background: Alzheimers disease is a progressive neurodegenerative disorder and the main cause of dementia in aging. Hippocampus is prone to changes in the early stages of Alzheimers disease. Detection and observation of the hippocampus…
In this paper, we studied the association between the change of structural brain volumes to the potential development of Alzheimer's disease (AD). Using a simple abstraction technique, we converted regional cortical and subcortical volume…
Recent studies have documented ocular changes in dementia patients, especially Alzheimer Disease (AD). In this study, we explored the change of eye size and eye shape in dementia, including AD patients. The eyeball volume and diameters were…
Alzheimer's disease (AD) is associated with local (e.g. brain tissue atrophy) and global brain changes (loss of cerebral connectivity), which can be detected by high-resolution structural magnetic resonance imaging. Conventionally, these…
Alzheimer's Disease (AD) is an irreversible neurodegenerative disorder affecting millions of individuals today. The prognosis of the disease solely depends on treating symptoms as they arise and proper caregiving, as there are no current…
Background and Objective: In brain imaging, geometric surface models are essential for analyzing the 3D shapes of anatomical structures. Alzheimer's disease (AD) is associated with significant cortical atrophy, making such shape analysis a…
Alzheimer's disease (AD), defined as an abnormal buildup of amyloid plaques and tau tangles in the brain can be diagnosed with high accuracy based on protein biomarkers via PET or CSF analysis. However, due to the invasive nature of…
Deep learning has become an important tool for Alzheimer's disease (AD) classification from structural MRI. Many existing studies analyze individual 2D slices extracted from MRI volumes, while clinical neuroimaging practice typically relies…
Analysis and quantification of brain structural changes, using Magnetic resonance imaging (MRI), are increasingly used to define novel biomarkers of brain pathologies, such as Alzheimer's disease (AD). Network-based models of the brain have…
Alzheimer's disease is a neurodegenerative condition that accelerates cognitive decline relative to normal aging. It is of critical scientific importance to gain a better understanding of early disease mechanisms in the brain to facilitate…
Saliency maps have been widely used to interpret deep learning classifiers for Alzheimer's disease (AD). However, since AD is heterogeneous and has multiple subtypes, the pathological mechanism of AD remains not fully understood and may…
Identifying and utilising various biomarkers for tracking Alzheimer's disease (AD) progression have received many recent attentions and enable helping clinicians make the prompt decisions. Traditional progression models focus on extracting…
Longitudinal assessment of brain atrophy, particularly in the hippocampus, is a well-studied biomarker for neurodegenerative diseases, such as Alzheimer's disease (AD). In clinical trials, estimation of brain progressive rates can be…